cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.3047163
title: Results from the monitoring of veterinary medicinal product residues and other substances in live animals and animal products - France

description: This dataset contains the monitoring results of veterinary medicinal product residues and other substances measured in live animals and animal products analysed by the national competent authority of France. The presence of unauthorised substances, residues of veterinary medicinal products or chemical contaminants in food may pose a risk factor for public health.

For this reason and in order to ensure a high level of consumer protection, a comprehensive legislative framework has been established in the European Union (EU) which defines maximum limits permitted in food and monitoring programmes for the control of the presence of these substances in the food chain. Regulation (EU) No 37/2010 establishes maximum limits for residues of veterinary medicinal products in food-producing animals and animal products. Maximum residue levels for pesticides in or on food and feed of plant and animal origin are laid down in Regulation (EC) No 396/2005. Commission Regulation (EC) 1881/2006 lays down the maximum limits for the presence of certain contaminants in animal products. Council Directive 96/23/EC lays down measures to monitor certain substances and residues thereof, mainly veterinary medicinal products, in live animals and animal products. Additionally, Commission Decision 97/747/EC lays down levels and frequencies of sampling for certain animal products.

The dataset contains the results of laboratory tests from samples taken from bovines, pigs, sheep, goats, horses, poultry, rabbits, farmed game, wild game aquaculture, milk, eggs and honey.

Targeted samples are taken with the aim of detecting illegal treatment or controlling compliance with the maximum levels laid down in the relevant legislation. This means that, in their national plans Member States target the groups of animals (species, gender, age) where the probability of finding residues is the highest.

Suspect samples are taken as a consequence of i) non-compliant results on samples taken in accordance with the monitoring plan, ii) possession or presence of prohibited substances at any point during manufacture, storage, distribution or sale through the food and feed production chain, or iii) suspicion or evidence of illegal treatment or non-compliance with the withdrawal period for an authorised medicinal veterinary product.

Residues of pharmacologically active substances mean active substances, excipients or degradation products and their metabolites, which remain in food.

Unauthorised substances or products mean substances or products prohibited under European Union legislation.

Non-compliant sample is a sample that has been analysed for the presence of one or more substances and failed to comply with the legal provisions for at least one substance. Thus, a sample can be non-compliant for one or more substances.
description: EU; CSV; data.collection@efsa.europa.eu
DOI: 10.5281/zenodo.3234178
title: Purification of HTT mutant samples 2019/05/17

description: <strong>Project: </strong>Investigation of purified HTT protein samples

<strong>Experiment: </strong>Purification of HTT mutant samples

<strong>Date completed:­ </strong>2019/05/27

<strong>Rationale: </strong>To assess HTT function <em>in vitro</em>
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234179
title: Purification of HTT mutant samples 2019/05/17

description: <strong>Project: </strong>Investigation of purified HTT protein samples

<strong>Experiment: </strong>Purification of HTT mutant samples

<strong>Date completed:­ </strong>2019/05/27

<strong>Rationale: </strong>To assess HTT function <em>in vitro</em>
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5519/qd.7hkkj5ay
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.5281/zenodo.3234181
title: Large-scale stringent purification of Q23 HTT and HTT-HAP40 using heparin affinity chromatography 2019/05/22

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein samples

<strong>Experiment: </strong>Large-scale stringent purification of Q23 HTT and HTT-HAP40 using heparin affinity chromatography

<strong>Date completed:­ </strong>2019/05/22

<strong>Rationale: </strong>Previous attempts to generate a much purer and homogenous HTT-HAP40 sample showed that the complex can bind heparin resin. In small-scale experiment, I also incorporated helpful suggestions from scientists at the CHDI Palm Springs meeting full-length HTT research breakout group i.e. ATP wash to remove HSP proteins. The experiment included 3 affinity chromatography steps with FLAG, heparin and NiNTA resin and finally a gel filtration step and yielded a highly pure HTT-HAP40 sample: https://zenodo.org/record/3234174.I now want to try this purification with apo HTT.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234182
title: Large-scale stringent purification of Q23 HTT and HTT-HAP40 using heparin affinity chromatography 2019/05/22

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein samples

<strong>Experiment: </strong>Large-scale stringent purification of Q23 HTT and HTT-HAP40 using heparin affinity chromatography

<strong>Date completed:­ </strong>2019/05/22

<strong>Rationale: </strong>Previous attempts to generate a much purer and homogenous HTT-HAP40 sample showed that the complex can bind heparin resin. In small-scale experiment, I also incorporated helpful suggestions from scientists at the CHDI Palm Springs meeting full-length HTT research breakout group i.e. ATP wash to remove HSP proteins. The experiment included 3 affinity chromatography steps with FLAG, heparin and NiNTA resin and finally a gel filtration step and yielded a highly pure HTT-HAP40 sample: https://zenodo.org/record/3234174.I now want to try this purification with apo HTT.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5519/qd.bnx04axq
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (88 records)
DOI: 10.5281/zenodo.3062262
title: Results from the monitoring of veterinary medicinal product residues and other substances in live animals and animal products - Slovenia

description: This dataset contains the monitoring results of veterinary medicinal product residues and other substances measured in live animals and animal products analysed by the national competent authority of Slovenia. The presence of unauthorised substances, residues of veterinary medicinal products or chemical contaminants in food may pose a risk factor for public health.

For this reason and in order to ensure a high level of consumer protection, a comprehensive legislative framework has been established in the European Union (EU) which defines maximum limits permitted in food and monitoring programmes for the control of the presence of these substances in the food chain. Regulation (EU) No 37/2010 establishes maximum limits for residues of veterinary medicinal products in food-producing animals and animal products. Maximum residue levels for pesticides in or on food and feed of plant and animal origin are laid down in Regulation (EC) No 396/2005. Commission Regulation (EC) 1881/2006 lays down the maximum limits for the presence of certain contaminants in animal products. Council Directive 96/23/EC lays down measures to monitor certain substances and residues thereof, mainly veterinary medicinal products, in live animals and animal products. Additionally, Commission Decision 97/747/EC lays down levels and frequencies of sampling for certain animal products.

The dataset contains the results of laboratory tests from samples taken from bovines, pigs, sheep, goats, horses, poultry, rabbits, farmed game, wild game aquaculture, milk, eggs and honey.

Targeted samples are taken with the aim of detecting illegal treatment or controlling compliance with the maximum levels laid down in the relevant legislation. This means that, in their national plans Member States target the groups of animals (species, gender, age) where the probability of finding residues is the highest.

Suspect samples are taken as a consequence of i) non-compliant results on samples taken in accordance with the monitoring plan, ii) possession or presence of prohibited substances at any point during manufacture, storage, distribution or sale through the food and feed production chain, or iii) suspicion or evidence of illegal treatment or non-compliance with the withdrawal period for an authorised medicinal veterinary product.

Residues of pharmacologically active substances mean active substances, excipients or degradation products and their metabolites, which remain in food.

Unauthorised substances or products mean substances or products prohibited under European Union legislation.

Non-compliant sample is a sample that has been analysed for the presence of one or more substances and failed to comply with the legal provisions for at least one substance. Thus, a sample can be non-compliant for one or more substances.
description: EU; CSV; data.collection@efsa.europa.eu
DOI: 10.14469/hpc/5714
title: Tris(4-bromophenyl)silane_C20

description: Tris(4-bromophenyl)silane_C20
DOI: 10.14469/hpc/5715
title: hexa(4-bromophenyl)disiloxane_C23

description: hexa(4-bromophenyl)disiloxane_C23
DOI: 10.17632/5vrgybfbg4.1
title: Data for: 3394403

description: The Web of Science database was used to search for game-based learning articles in science education.
DOI: 10.17632/mchc82n75d.1
title: Data for: Inhibition of HIV-1 envelope-dependent membrane fusion by serum anti-lymphocyte autoantibodies is associated with low plasma viral load

description: Complementary results showing: Suppl. Data 1: Lack of relationship of total anti-lymphocyte antibody (ALA) levels, as measured on Jurkat CD4+ (A) or CD4-negative cells (B), with fusion inhibition, viral load or CD4 cell count. Suppl. Data 2: Antinuclear antibodies (ANA)-staining patterns for sera from 30 healthy control individuals and 38 HIV+ patients.
DOI: 10.17632/wsyhyf89d5.1
title: Design of Complex Engineered System and the Effectiveness of Organizational Networks

description: This dataset presents data collect during research for my Ph.D. dissertation in Industrial and Systems Engineering at the University of Rhode Island in 2017-2018. Research Purpose Cost and schedule overruns have become increasingly common in large defense programs that attempt to build systems with improved performance and lifecycle characteristics, often using novel, untested, and complex product architectures. Based on the well documented relationship between product architecture and the structure of the product development organization, research examined the effectiveness of different organizational networks at designing complex engineered systems, comparing the performance or real-world organizations to ideal ones. Method and Research Questions Phase 1 examined information exchange models and implemented the model of information exchange proposed by Dodds, Watts and Sabel to confirm the model can be successfully implemented using agent-based models (ABM). Phase 2 examined artifact models and extended the information exchange model to include the processing artifacts. Phase 3 examined smart team models and phase 4 applied information exchange and artifact models to a real-world organization. Research questions: 1) How do random, multi-scale, military staff and matrix organizational networks perform in the information exchange and artifact task environments and how does increasing the degree of complexity affect performance? 2) How do military staff and matrix organizational networks (real organizations) perform compared to one another and to random and multi-scale networks (ideal organizations)? How does increasing degree of complexity affect performance and which structure is preferred for organizations that design complex engineered systems? 3) How can organizational networks be modified to improve performance? Data Interpretation Excel spreadsheets summarize and analyze data collected from MATLAB and NetLogo ABM experiments for each phase. In general, raw data was collected in a 'data' worksheet, and then additional worksheets and graphs were created to analyze data. Dataset includes link to associated dissertation, which provides further detail. Notable Findings 1) All organizational networks perform well in the information exchange environment and in the artifact environment when complexity is low to moderate. 2) Military staff networks consistently out-perform matrix networks. 3) At high complexity, all networks are susceptible to congestion failure. 4) Military staff organizational networks exhibit performance comparable to multi-scale networks over a range of situations.
DOI: 10.25912/5cede0024b1e1
title: NHST practices in top cited Information Systems papers 2013-2016
DOI: 10.25919/5cee725996fd3
title: Parkes observations for project P456 semester 2019APRS_19

description: The Parkes Pulsar Timing Array (PPTA) project has three primary goals: (a) detection of gravitational waves from astronomical sources, (b) establishment of a pulsar timescale, and (c) improvement of our understanding of Solar-system dynamics. The PPTA is the oldest of three international pulsar timing groups. We have the smallest telescope and the smallest group, but the best measurements and the best results. Our bound on the strength of the incoherent gravitational wave background is the only bound which significantly constrains theoretical models. We have maintained our leading position because: we have the southern sky; we have a small but well-focussed group; we have the best-calibrated receivers; and we have been able to observe with an almost regular cadence of 15 to 20 days over a wide bandwidth. With this proposal we aim to maintain our pre-eminent position in the field.

Unlike most observing proposals, this is a continuing proposal for which the observations will continue to improve bounds on ultra-low-frequency gravitational waves until they are finally detected. Continued Parkes observations will remain valuable at least until the first stage of the SKA is able to improve on our sensitivity and observing cadence. Even after the gravitational wave background is detected we will want to continue observations in support of the nascent field of gravitational wave astronomy!
DOI: 10.14469/hpc/5716
title: 1,3-bis(4-carboxyphenyl)-1,1,3,3-tetramethyldisiloxane_L4-H2

description: 1,3-bis(4-carboxyphenyl)-1,1,3,3-tetramethyldisiloxane_L4-H2
DOI: 10.17632/bxh46tps75.3
title: 2D Bin Packing and Scheduling Online Printing Company

description: These data belongs to an actual printing company . Each record in Excel file Raw Data/Big_Data present an order from customers. In column "ColorMode" ; 4+0 means the order is one sided and 4+4 means it is two-sided. Files in Instances folder correspond to the instances used for computational tests in the article. Each of these instances has two related file with the same characteristics. One with gdx suffix and one with out any file extension. These files are used to import data to the python implementation. The code and relevant description can be found in Read_input.py file.
DOI: 10.17632/c38pppfh4n.1
title: Raw materials procurement strategies at the Ciota Ciara cave: new insight on land mobility in north-western Italy during Middle Palaeolithic

description: The importance of the Ciota Ciara cave for the understanding of the Middle Palaeolithic peopling of Piedmont (north-western Italy) is known since the 60s but it is just since 2009 that systematic and multidisciplinary archaeological excavations are ongoing at the site. In this region, studies about Palaeolithic are quite underdeveloped and the proposed research represents the first attempt to understand Middle Palaeolithic land mobility in the region. The lithic assemblage found is composed by 7046 artefacts and different raw materials are involved in the production of lithic artefacts. Vein quartz is the main exploited raw material in all the archaeological layers followed by spongolite, a local variety of chert, and by a better-quality grey/black flint. For these rocks the reduction sequences are complete while other raw materials are sporadically attested all along the sequence (opal, jasper and milonite) and probably exploited out of the site. Rhyolite and radiolarite are present in different proportions in all the archaeological levels and are represented almost exclusively by retouched tools and by small flakes belonging to the reshaping or re-sharpening of the tools’ edges. The proposed research focuses on the identification of the supply areas of lithic raw materials in order to define the land mobility of the human groups that inhabited the cave during Middle Palaeolithic. The study involves both local and allochthonous raw materials to understand the mobility range on a local and sub-regional scale. Starting from the idea of evolutionary chain, a specific methodology has been developed for vein quartz, aimed at the identification of the most probable secondary sources exploited. For all the raw materials, field works and lab analysis (stereomicroscope observations, Scanning Electron Microscopy and µ-XRF analysis) have been set up. The results obtained show that several local primary and secondary deposits were exploited, located at few hundred meters from the site. Vein quartz was collected in secondary deposits at the base of the mount while rhyolite comes from secondary deposits located at about 2 km in a straight line from the site. Radiolarite was instead collected within deposits located at distance between 20 and 30 km from the Ciota Ciara cave giving the chance to formulate reliable hypothesis on the seasonal mobility of the Middle Palaeolithic hunter-gatherers of the Ciota Ciara cave.
DOI: 10.5063/f1pk0df9
title: Locations of sediment ecotypes of surfgrass (Phyllospadix spp.) along the west coast of North America (1996 to 2019)

description: This dataset provides the coordinates for observations of different species of surfgrass (genus Phyllospadix) that were growing rooted in sediment rather than attached to rock. There are 51 locations provided. These observations were collected by a network of coastal scientists and the description/results of the work are reported in a peer-reviewed article entitled "Between a rock and a soft place: surfgrass colonizes sediments without attachment to rock" (published in the journal Ecology in 2019). These data are novel because previous observations on all members of Phyllospadix indicate that included species obligately attached to only rock; these are the first observations of recruitment in soft-sediment habitats.
DOI: 10.7910/dvn/psik4q/3fx9n0
title: client_codebook.xlsx

description: Codebook
DOI: 10.7910/dvn/psik4q/hqydmn
title: 1106971_Burkina_IDI_guide_comm_rep_v1.0_clean.docx

description: IDI-guide_community-representatives
DOI: 10.7910/dvn/psik4q/knsos1
title: 1106971_Burkina_IDI_guide_gov_official_v1.0_clean.docx

description: IDI-guide_government-officials
DOI: 10.7910/dvn/psik4q/ny7ad6
title: client_deid.tab

description: De-identified client data
DOI: 10.14469/hpc/5717
title: (4-bromophenyl)dimethylsilane_C22

description: (4-bromophenyl)dimethylsilane_C22
DOI: 10.14469/hpc/5718
title: 1,3-bis(4-bromophenyl)-1,1,3,3-tetramethyldisiloxane_C25

description: 1,3-bis(4-bromophenyl)-1,1,3,3-tetramethyldisiloxane_C25
DOI: 10.14469/hpc/5719
title: Bis(4-carboxyphenyl)methylsilanol_L6-H2

description: Bis(4-carboxyphenyl)methylsilanol_L6-H2
DOI: 10.17632/bxh46tps75.4
title: Customers order for a Printing Company (2D Bin Packing and Scheduling)

description: These data belongs to an actual printing company . Each record in Excel file Raw Data/Big_Data present an order from customers. In column "ColorMode" ; 4+0 means the order is one sided and 4+4 means it is two-sided. Files in Instances folder correspond to the instances used for computational tests in the article. Each of these instances has two related file with the same characteristics. One with gdx suffix and one with out any file extension. These files are used to import data to the python implementation. The code and relevant description can be found in Read_input.py file.
DOI: 10.7910/dvn/psik4q/vfxt0w
title: 1106971_Burkina_IDI_guide_provider_v1.0_clean.docx

description: IDI-guide_providers
DOI: 10.14469/hpc/5720
title: 1,1,1,5,5,5-hexakis(4-carboxyphenyl)-3,3-dimethyltrisiloxane_L7-H6

description: 1,1,1,5,5,5-hexakis(4-carboxyphenyl)-3,3-dimethyltrisiloxane_L7-H6
DOI: 10.14469/hpc/5721
title: Tris(4-bromophenyl)silanol_C26

description: Tris(4-bromophenyl)silanol_C26
DOI: 10.17632/65zmcyxyc8.1
title: Data for: Valuing Companies by Cash Flow Discounting: Ten Methods and Nine Theories

description: Data for Valuing Companies by Cash Flow Discounting: Ten Methods and Nine Theories